Global Cancer Cachexia Market

Cancer Cachexia Market Size, Share, Growth Analysis, By Product(Progestogens, Corticosteroids, Combination Therapies, and Others), By Distribution Channels(Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Mechanism of Action(Appetite Stimulators and Weight Loss Stabilizers), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35A2857 | Region: Global | Published Date: March, 2024
Pages: 185 | Tables: 89 | Figures: 72

Cancer Cachexia Market Insights

Global Cancer Cachexia Market size was valued at USD 2.31 Billion in 2022 and is poised to grow from USD 2.42 Billion in 2023 to USD 3.47 Billion by 2031, growing at a CAGR of 4.6% in the forecast period (2024-2031)

According to data released by the National Center for Biotechnology Information (NCBI), the prevalence of cachexia in patients with advanced cancer is estimated at 80.0%. Globally, cachexia accounts for 20.0% of cancer deaths. It is a wasting disorder characterized by weight loss, anorexia, osteoporosis and anemia in patients. It is commonly associated with chronic diseases such as cancer, renal failure, chronic obstructive pulmonary disease (COPD), and HIV. Cancer-induced cachexia is associated with the presence of tumors. According to the Cancer Cachexia Hub, the condition affects an estimated 1.3 million cancer patients in the US. only annually.

Cancer cachexia is a multifaceted disease characterized by involuntary weight loss, muscle wasting, and metabolic abnormalities commonly associated with cancer cachexia market treatment experiences and induces a variety of growth stimulants opportunities impact the event and contribute to the overall cancer cachexia market growth and potential. The global increase in cancer implies a corresponding increase in the prevalence of cancer cachexia, thus increasing the market potential of cancer cachexia. The increasing prevalence of cancer establishes a large patient cohort, promoting opportunities for the development of potential therapies and therapeutic interventions targeting cancer cachexia. Older individuals are more susceptible to cancer, increasing the risk of cancer cachexia. The aging population in many countries highlights huge market opportunities for therapies that address cancer-related challenges including cachexia, thereby driving cancer cachexia into the market.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Cancer Cachexia Market size was valued at USD 2.31 Billion in 2022 and is poised to grow from USD 2.42 Billion in 2023 to USD 3.47 Billion by 2031, growing at a CAGR of 4.6% in the forecast period (2024-2031)

The competitive environment of the Cancer Cachexia Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Established organizations within the industry leverage techniques inclusive of product innovation, strategic partnerships, and mergers and acquisitions to strengthen their market position. Additionally, the market is witnessing elevated opposition from local and neighborhood producers supplying cost-powerful options. 'Aeterna Zentaris', 'Aphios Corporation', 'Bristol-Myers Squibb Company', 'Pfizer Inc.', 'Helsinn Group', 'Merck KGaA', 'Artelo Biosciences Inc.', 'NGM Biopharmaceuticals', 'Aveo Oncology', 'Aavogen Inc.', 'Green Cross Wellbeing Corporation', 'Cannabics Pharmaceuticals Inc.', 'TCI Peptide Therapeutics', 'Fresenius Kabi', 'Tetra Bio-Pharma', 'Actimed Therapeutics'

Current treatment options for cachexia in cancer patients are limited to drugs such as progestogens, corticosteroids, and others. These drugs have shown efficacy in the treatment of cancer-induced cachexia, although there are clinical differences in treatment outcomes and no drug candidates are currently approved specifically for this condition. This increases the gap in therapeutic options, which market players are aiming to fill through R&D and the introduction of new drugs in the market.

In many cases, traditional approaches to treating patients with single-drug interventions provided limited therapeutic benefit. Also, due to the lack of approved drugs for this condition, healthcare providers have been seen turning to combination therapies to treat illness including both pharmacological and non-pharmacological. Clinical trials show significant improvement in body does not deny (LBM) in treated patients and combination therapies. Thus, such outcomes as the popularity of health professionals increase the acceptability of combination therapy among patient populations and drive the demand for cancer cachexia treatments in the market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Cancer Cachexia Market

Report ID: SQMIG35A2857

$5,300
BUY NOW GET FREE SAMPLE